71 related articles for article (PubMed ID: 24797881)
1. The effect of lipocisplatin on cisplatin efficacy and nephrotoxicity in malignant breast cancer treatment.
Li Q; Tian Y; Li D; Sun J; Shi D; Fang L; Gao Y; Liu H
Biomaterials; 2014 Aug; 35(24):6462-72. PubMed ID: 24797881
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis.
Li M; Tang Z; Zhang Y; Lv S; Li Q; Chen X
Acta Biomater; 2015 May; 18():132-43. PubMed ID: 25735801
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
5. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts.
Boulikas T
Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951
[TBL] [Abstract][Full Text] [Related]
6. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
8. Anti-platelet agents augment cisplatin nanoparticle cytotoxicity by enhancing tumor vasculature permeability and drug delivery.
Pandey A; Sarangi S; Chien K; Sengupta P; Papa AL; Basu S; Sengupta S
Nanotechnology; 2014 Nov; 25(44):445101. PubMed ID: 25302488
[TBL] [Abstract][Full Text] [Related]
9. A New Highlight of
Sioud F; Amor S; Toumia IB; Lahmar A; Aires V; Chekir-Ghedira L; Delmas D
Cells; 2020 Feb; 9(2):. PubMed ID: 32033130
[TBL] [Abstract][Full Text] [Related]
10. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
Tikoo K; Ali IY; Gupta J; Gupta C
Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570
[TBL] [Abstract][Full Text] [Related]
12. A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
Xiao H; Song H; Yang Q; Cai H; Qi R; Yan L; Liu S; Zheng Y; Huang Y; Liu T; Jing X
Biomaterials; 2012 Sep; 33(27):6507-19. PubMed ID: 22727463
[TBL] [Abstract][Full Text] [Related]
13. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
14. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
[TBL] [Abstract][Full Text] [Related]
15. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
16. Solid lipid nanoparticles of anticancer drugs against MCF-7 cell line and a murine breast cancer model.
Zhuang YG; Xu B; Huang F; Wu JJ; Chen S
Pharmazie; 2012 Nov; 67(11):925-9. PubMed ID: 23210242
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model.
Liu CM; Lee WC; Yu CY; Lan KL; Chang CH; Ting G; Lee TW
Oncol Rep; 2012 Mar; 27(3):678-84. PubMed ID: 22109644
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
Guo JH
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
